Randomized controlled trial of Qishen Zhixuan Formula in treating posterior circulation ischemia-induced isolated vertigo
Objective To investigate the efficacy of Qishen Zhixuan Formula(QSZXF)in treating posterior circulation ischemia-induced isolated vertigo and its effects on hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),and D-dimer(DD).Methods A total of 97 patients with posterior circulation ischemia-induced isolated vertigo who presented the Encephalopathy Department of Beijing Huairou Hospital of Traditional Chinese Medicine from January 2022 to December 2023 were randomized into control group(n=48)and research group(n=49)using random number table method.The control group received conventional Western medicine treatment,while the research group was treated with QSZXF in addition to the treatment of control group.The treatment course lasted for two weeks for both groups The efficacy,traditional Chinese medicine syndrome scores,dizziness handicap inventory(DHI)score,and changes in serum hs-CRP,IL-6 and DD levels were compared between the two groups.Results The effective rate of the research group(95.74％)was higher than that of the control group(78.26％);the improvement in the traditional Chinese medicine syndrome scores and DHI scores of the research group was better than that of the control group(P＜0.05);hs-CRP,IL-6,and DD levels of the research group decreased more significantly compared to those in the control group(P＜0.05);no patients in either group experienced any liver or kidney dysfunction or allergic reactions.Conclusion The treatment with QSZXF for posterior circulation ischemia-induced isolated vertigo can relieve symptoms of the CM pattern,alleviate vertigo,enhance therapeutic efficacy,and reduce levels of hs-CRP,IL-6,and DD in patients.
万方数据
维普
